In recent years, there has been an increase in the incidence of breast cancer (BC) in women in all economically developed countries. Currently, 6,4 million women with BC, who have been living for 5 years or more are registered. According to the latest scientific literature, the incidence of BC has increased by 20%, and mortality by 14% [2, 5, 7, 13].

Treatment of HER2-positive BC is a complex and significant task in practical and scientific oncology.